Skip to main content
. 2022 Sep 23;12(4):4250–4258. doi: 10.1002/cam4.5292

FIGURE 1.

FIGURE 1

Molecular efficacy of the TM5614 combination. (A) Cumulative incidences of a MR4.5 conversion by 48 weeks. Eleven patients (33.3% [95% confidence interval (CI), 18.0%–51.8%]) achieved MR4.5 during 48 weeks. The median time to MR4.5 was 8 weeks [95% CI, 4–24]. (B) BCR‐ABL IS % kinetics within 48 weeks. Boxes, 5–95 percentiles; horizontal bars, median; vertical brackets, ranges.